Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives $4.79 Consensus PT from Analysts
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Free Report) has received a consensus recommendation of “Hold” from the ten analysts that are covering the stock, MarketBeat.com reports. Seven analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average […]
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Free Report) has received a consensus recommendation of “Hold” from the ten analysts that are covering the stock, MarketBeat.com reports. Seven analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average […]
